Arturo Loaiza-Bonilla MD, MSEd


COVID-19 and Its Impact on Oncology Clinical Trials

Coronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.

Margaret E. Gatti-Mays, MD, MPH, FACP


Breast Cancer Awareness Month: Recent Developments and Future Directions for Immunotherapy Treatment

Margaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.

Nilanjan Ghosh, MD


Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL Therapy

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.

Nancy Y. Lee, MD, FASTRO


JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.

Hagen F. Kennecke, MD, MHA, FRCP


Making Treatment and Screening Decisions for Patients With Prostate Cancer

Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.

Theodore W. Laetsch, MD


Larotrectinib Does Not Increase Risk of Fractures for Thyroid Cancer

Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.

Murugesan Manoharan, MD, FRACS


Rise in Prostate Cancer Cases Contributes to Challenges in Care

Murugesan Manoharan, MD, FRACS, offers observations about prostate cancer care at Miami Cancer Institute.

Christopher Pleyer, MD


Exploring Preliminary Results of Ibrutinib and Fludarabine in CLL

Christopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Ruta D. Rao, MD


Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBC

Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Tanyatorn Ghanjanasak, DO


Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma

A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.

Wojciech Jurczak, MD, PhD


Treatment Options After Relapse in CLL

Wojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.

Maisey Ratcliffe, MPH


Management of HR+, HER2- Early-Stage Breast Cancer After Diagnosis

Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.

Thomas Roby, MD


Considerations for Oncologists During Chemotherapy Shortages

Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.

Thomas Cluzeau, MD, PhD


Azacitidine Plus APR-246 Appears Promising as Treatment of TP53-Mutant MDS and AML

Thomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Pashna Munshi, MD


Future Directions in GVHD

Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.

Fadi Haddad, MD


Background on the Phase 2 Study of Ponatinib/Blinatumomab in Ph+ ALL

Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Anjana Pillai, MD


Evaluating Current Challenges in Hepatocellular Carcinoma

Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.

Jason Westin, MD, MS, FACP


Ever-Changing Treatment Landscape of Aggressive B-Cell Lymphoma

Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.

Andrew Spencer, MD, MBBS


Revised Panobinostat Combination Shows Efficacy in Multiple Myeloma

Andrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.

Rohan Garje, MD


Kidney Cancer Awareness Month: Assessing Best Treatment Options in RCC

In an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.

Hearn Cho, Md, PhD


Cho Provides Background on the Multiple Myeloma Research Foundation’s CureCloud Study

Hearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.

Sailaja Darisipudi


Elacestrant Outperforms SOC in Terms of PFS in ER+/HER2– mBC

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.

Jennifer Gass, PhD, FACMG


World Cancer Day: Next Generation Sequencing at the Forefront of Precision Medicine

Next generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.

Adam Weiner, MD


Research Explores Molecular Subtyping in Prostate Cancer.

Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.

Ariana Pelosci


Clinical Benefit Seen With Olaparib/Selumetinib in RAS-Mutated Ovarian and Endometrial Cancers

The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.

David W. Dougherty, MD


Telehealth Becomes Mainstream in Oncology Practices

David W. Dougherty, MD, MBA, discusses telemedicine in oncology after emergence of COVID-19.

Gary K. Schwartz, MD


Investigators Observe Differences in Toxicity for Sarcoma Due to Dosing

Gary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.